Oncolytic Vaccinia Virus in Lung Cancer Vaccines
Cao-Sang Truong, So Young Yoo
Abstract
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vaccines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.
Topics & Concepts
Oncolytic virusVacciniaLung cancerImmunotherapyMedicineCancerCancer vaccineVirusImmune systemCancer immunotherapyImmunologyTreatment of lung cancerCancer researchVirologyOncologyBiologyInternal medicineRecombinant DNABiochemistryGeneVirus-based gene therapy researchImmunotherapy and Immune ResponsesCAR-T cell therapy research